National Alliance for Eye and Vision Research
Advocacy Center
Become an Advocate for Vision Research
Eye Fact Center
Press Center
Newsletters
Spread the Word
Tell Your Story
Link to Our Site
Resources and Links
Privacy Policy
Site Map
Press Center
About the Alliance National Eye Institute Contact Us
Become an Advocate for Vision Research - Join the Action List
Speak Up for Eye and Vision Research
Enter Your Zip Code   
 
FOR IMMEDIATE RELEASE
September 19, 2006
CONTACT: James F. Jorkasky
Executive Director
240-221-2905
jamesj@eyeresearch.org

Congressional Briefing Emphasizes Impact of Collaboration in Diabetic Retinopathy Research

Dr. Tom Gardner with Congressman Gene Green
Dr. Tom Gardner with Congressman Gene Green
Collaboration was the watchword at the September 19, 2006, Alliance for Eye and Vision Research (AEVR) congressional briefing on the impact of research partnerships at the National Eye Institute (NEI) in the fight against diabetic retinopathy. The briefing, held in conjunction with the American Diabetes Association (ADA) and the Juvenile Diabetes Research Foundation International (JDRF), featured Dr. Thomas Gardner, a diabetes researcher and clinician from the Pennsylvania State University Milton S. Hershey Medical Center, a site within the Diabetic Retinopathy Clinical Research (DRCR) Network.

The DRCR, funded by NEI in partnership with JDRF, is a collaboration of clinicians and researchers from different specialties throughout the nation and at the National Institutes of Health (NIH) who are combining their skills and assets to accelerate discoveries about the causes of diabetic retinopathy and to develop preventions, treatments and cures for this potentially blinding condition. NIH estimates that 21 million Americans have diabetes, and most of these individuals will experience vision problems related to this condition.

"The eye is a complex structure, so the collaborative nature of the Network enables it to quickly respond with basic and clinical research into the most promising new findings," said Dr. Gardner, who added that, in its first four years, the Network has grown to include 545 experts at 163 clinical sites (many community-based) in 43 states seeing more than 1,700 patients - many of whom would not have otherwise had access to this care.

Dr. Gardner acknowledged that he understands diabetes and its consequences from a personal and professional perspective, due to both his brothers having diabetes. That personal experience with this disease was also expressed by Cong. Gene Green (D-TX), who introduced Dr. Gardner. Cong. Green, a co-chair of the Congressional Vision Caucus and a member of the House Energy and Commerce Committee with oversight over the NIH, represents a largely Hispanic district in which the incidence of diabetes and diabetic retinopathy is especially high. Since the Committee was preparing for an afternoon hearing on an NIH reauthorization bill that would establish a "common fund" for collaborative research, he commented that, "Itís fitting that weíre here on this particular day, as I canít emphasize trans-NIH research too much as a way to lift the disease burden on the American people. Disease doesnít occur in isolation, nor should the research."

Earlier that day, Dr. Gardner met with Senator Arlen Specter (R-PA) and Senator Rick Santorum (R-PA), as well a staff member from the office of Cong. Tim Holden (D-PA), to advocate for research funding.

Dr. Gardner with Senator Arlen Specter
Dr. Gardner with Senator Arlen Specter
Dr. Tom Gardner with Senator Rick Santorum
Dr. Gardner with Senator Rick Santorum

The DRCR is just one of several networks which NEI has funded over the past 30 years in collaboration with the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) to study diabetic retinopathy, which have resulted in treatments that have reduced blindness by 90 percent and save $1.6 billion annually in healthcare costs. NEI has also collaborated with the National Cancer Institute (NCI) on research into factors that inhibit blood vessel growth in tumors that are now being applied to diabetic retinopathy and age-related macular degeneration (AMD) therapies. NEI collaborative research with the National Human Genome Research Institute (NHGRI) has resulted in the discovery of gene variants in the bodyís inflammatory response associated with increased risk of AMD that may also relate to diabetic retinopathy.

Information on the DRCR Network is available at: www.DRCR.net. An NEI-generated diabetic retinopathy fact sheet is available at: http://www.nih.gov/about/researchresultsforthepublic/. An Autumn 2006 NIH Medline Plus cover story on diabetes is at http://www.fnlm.org/magazine/autumn2006.pdf.